MakroCare has been selected by a promising US biotech organisation to help a major Cancer registry program by collecting real world data.
Online PR News – 02-September-2017 – Princeton , NJ – MakroCare has been selected by a growing US biotech company for a registry program to create around 1500 cancer patient data. MakroCare, specialized in RWE and outcomes research, has been engaged to offer services for protocol design/writing, data collection, data monitoring, analysis, and reports. MakroCare will also be providing its proprietary technology platform for individual site branding, data collection & review, analytics consisting of 100 sites. In addition, MakroCare will be working with sponsor to design, and launch site specific websites for physicians to keep them updated with published data, news & notifications throughout this program.
The objective of this registry is to collect real-world data focusing on treatment decision impact, outcomes in the management of cancer patients and clinical utilization of the diagnostic platform in various cancer patients. This multicenter, non-randomized, single arm, real-world data collection registry is expected to enroll around 1500+ patients over next several years. Some of the key outcomes of this registry would be clinical utilization pattern, treatment-decision impact, clinical benefits rate and objective response rate.
As RWE and outcomes research are becoming increasingly important and necessary for product development and commercialization, MakroCare brings to table technology integrated, cost efficient, non-traditional solutions to support companies in this space.